Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa
Related Experiment Video
Updated: Aug 8, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
L Trzeciak1, E Hennig, J Kolodziejski
1Department of Gastroenterology, Medical Centre for Postgraduate Education, Cancer Center, Institute of Oncology, ul. Roentgena 5, 02-781, Warsaw, Poland.
Abstract:
The status of CDKN2a gene, coding for p16 and p19ARF proteins, was examined in 55 colorectal cancers. Polymerase chain reaction (PCR), single stranded conformational polymorphism and sequencing revealed 1 case of CDKN2a mutation. Methylation-specific PCR detected p16 locus methylation in 37 (73%) of 51 normal samples and 29 (53%) of 55 cancers (P=0.035). p16 transcript absence (assessed by reverse transcription-polymerase chain reaction) was noted in 10 (45%) of 22 normal samples and four (14%) of 29 cancers (P=0.012) and correlated with gene methylation (P=0.036). The decreasing frequency of p16 silencing in cancer comparing to normal mucosa does not support the postulated role of p16 in colorectal carcinogenesis.
Related Concept Videos
Epigenetic Regulation
Inhibition of Cdk Activity
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Epigenetic Regulation
X-chromosome...

